outcome of Deep Brain Stimulation, the principal investigator developing a database of patients who have received DBS at the University of Kentucky, and the study manager for an industry sponsored Phase II study of cell therapy delivery. Dr. Quintero earned his undergraduate degree in Biology at the University of North Carolina at Chapel Hill. Beginning with his postdoctoral work in the laboratory of Dr. Greg Gerhardt at the University of Kentucky, he helped develop and use biosensors to understand the neurochemical communication of the brain. The methodology he developed is being used throughout the world, and he has trained dozens of investigators at dozens of universities, research centers, and companies throughout North America, South America, Europe, and Asia. These investigators have used this technique in their own experiments and made it part of their subsequent publications.
Professor Christian Hölscher, Lancaster University, presented his work with the future of GLP-1 agonists combined with GIP agonists. These two groups of drugs are collectively called dual agonists – both are incretin hormones that work on a similar pathway to reduce insulin resistance and increase insulin signalling. Early indications in models of Parkinson's are revealing that, when combined, these drugs are potentially more potent on the movement aspects of the condition. There is further evidence they reduce oxidative stress and mitochondrial damage by reducing the activation of the inflammatory response . Importantly, these drugs also permeate through the blood brain barrier and seem to promote cell survival. However these dual agonists need to be tested in multiple models of Parkinson’s, such as an alpha-synuclein model, before they can progress into trials in people living with Parkinson’s.